{
  "meta": {
    "data_length": 1,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A330",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004109,
    "timestamp_received": "2026-09-25T00:14:09.220268+00:00Z",
    "timestamp_returned": "2026-09-25T00:14:09.224377+00:00Z",
    "trace_id": "7bc83c0f-75f5-4d05-8e5d-97713afda973"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:fda:keytruda:8:1",
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-30:0",
          "type": "Contribution",
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda:keytruda",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Keytruda (pembrolizumab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514Orig1s186lbl.pdf. Revised February 2026. Accessed March 2, 2026.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514Orig1s186lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Merck Sharp & Dohme Corp.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Keytruda",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "pembrolizumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2014-09-04",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 125514,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2026-02-10",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:330",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:oncotree:ESCA",
          "conceptType": "Disease",
          "name": "Esophageal Adenocarcinoma",
          "mappings": [],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:oncotree:ESCA",
            "code": "ESCA",
            "name": "Esophageal Adenocarcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCA"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C106432",
          "conceptType": "Therapy",
          "name": "Pembrolizumab",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:1547545",
                "code": "1547545",
                "name": "pembrolizumab",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1547545"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:45775965",
                "code": "45775965",
                "name": "pembrolizumab",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/45775965"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:sctid:716125002",
                "code": "716125002",
                "name": "Pembrolizumab",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=716125002&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:37396350",
                "code": "37396350",
                "name": "Pembrolizumab",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/37396350"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "PD-1/PD-L1 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Immunotherapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C106432",
            "code": "C106432",
            "name": "Pembrolizumab",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:41",
                "present": true,
                "subject": {
                  "id": "bmkr:41",
                  "type": "CategoricalVariant",
                  "name": "PD-L1 (CPS) >= 10",
                  "constraints": [],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Protein expression"
                    },
                    {
                      "name": "marker",
                      "value": "PD-L1"
                    },
                    {
                      "name": "unit",
                      "value": "Combined Positive Score (CPS)"
                    },
                    {
                      "name": "equality",
                      "value": ">="
                    },
                    {
                      "name": "value",
                      "value": 10
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "25.01d",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:fda:keytruda:8",
            "type": "Indication",
            "description": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10) as determined by an FDA-approved test.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-10-30:0",
                "type": "Contribution",
                "description": "Initial access of FDA approvals",
                "date": "2024-10-30",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:fda:keytruda",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Keytruda (pembrolizumab) [package insert]. FDA.",
                "title": null,
                "aliases": [],
                "description": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514Orig1s186lbl.pdf. Revised February 2026. Accessed March 2, 2026.",
                "urls": [
                  "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514Orig1s186lbl.pdf",
                  "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:fda",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Food and Drug Administration",
                      "description": "Regulatory agency that approves drugs for use in the United States."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Merck Sharp & Dohme Corp.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Keytruda",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "pembrolizumab",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2014-09-04",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": 125514,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2026-02-10",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}